Precisely what selective pressures drive the loss of 53BP1 and USP28 in cancer remains to be determined, but current data supports the proposition that MSP gene status could be used as a potential biomarker for poor responses to antimitotic drugs in cancer (Figure 2) (Meitinger et al., 2024). The gene discussed is TP53BP1; the disease is cancer.